Buy MACI Pullback: Vericel (VCEL) for Regenerative Knee Cartilage Expansion
Vericel's MACI franchise remains the company's growth engine: Q2 2026 MACI revenue grew 23% and management raised full-year guidance to $330-$340M while authorizing a $200M buyback. The shares have pulled back from the summer high, offering a mid-term trade on continued adoption, margin leverage and capital return. Trade plan: enter $39.60, stop $3…